a b s t r a c t a r t i c l e i n f o
We investigated two measures of neural integrity, T1-weighted volumetric measures and diffusion tensor imaging (DTI), and explored their combined potential to differentiate pre-diagnosis Huntington's disease (pre-HD) individuals from healthy controls. We applied quadratic discriminant analysis (QDA) to discriminate pre-HD individuals from controls and we utilised feature selection and dimension reduction to increase the robustness of the discrimination method. Thirty six symptomatic HD (symp-HD), 35 pre-HD, and 36 control individuals participated as part of the IMAGE-HD study and underwent T1-weighted MRI, and DTI using a Siemens 3 Tesla scanner. Volume and DTI measures [mean diffusivity (MD) and fractional anisotropy (FA)] were calculated for each group within five regions of interest (ROI; caudate, putamen, pallidum, accumbens and thalamus). QDA was then performed in a stepwise manner to differentiate pre-HD individuals from controls, based initially on unimodal analysis of motor or neurocognitive measures, or on volume, MD or FA measures from within the caudate, pallidum and putamen. We then tested for potential improvements to this model, by examining multi-modal MRI classifications (volume, FA and MD), and also included motor and neurocognitive measures, and additional brain regions (i.e., accumbens and thalamus). Volume, MD and FA differed across the three groups, with pre-HD characterised by significant volumetric reductions and increased FA within caudate, putamen and pallidum, relative to controls. The QDA results demonstrated that the differentiation of pre-HD from controls was highly accurate when both volumetric and diffusion data sets from basal ganglia (BG) regions were used. The highest discriminative accuracy however was achieved in a multi-modality approach and when including all available measures: motor and neurocognitive scores and multi-modal MRI measures from the BG, accumbens and thalamus. Our QDA findings provide evidence that combined multi-modal imaging measures can accurately classify individuals up to 15 years prior to onset when therapeutic intervention is likely to have maximal effects in slowing the trajectory of disease development.
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Introduction
Modern neuroimaging techniques enable the examination of central nervous system neuropathology in vivo. As analytical neuroimaging methods mature, the number of measures of neuronal integrity which can be accurately measured is increasing. With these advances there are parallel efforts to establish increasingly sensitive and reliable imaging biomarkers of disease onset and progression in Huntington's disease (HD) (for reviews see Bohanna et al., 2008; Esmaeilzadeh et al., 2011; Georgiou-Karistianis, 2009; Paulsen, 2009) . The period prior to HD clinical onset is commonly known as the preclinical phase (or pre-HD). The ability to estimate proximity to disease diagnosis (e.g., Langbehn et al., 2004) provides a significant opportunity to investigate neurobiological changes during this period. There are a number of important issues in Neurobiology of Disease 51 (2013) 82-92 
